Serotonin receptor agonist · Serotonin 5-HT2A receptor agonist · Serotonergic psychedelic · Hallucinogen

MSP-2020

Original Wikipedia articleen.wikipedia.org/wiki/MSP-2020 revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Overview

MSP-2020 is a psychedelic drug of the tryptamine and pyrrolidinylmethylindole families related to psilocybin which is under development for the treatment of mental disorders such as major depressive disorder. It is taken orally. The drug acts as a serotonin 5-HT2A receptor agonist and is described as a prodrug. It is a 3-pyrrolidine–indole derivative and hence cyclized tryptamine and is said to be psilocybin-like but with stronger effects and a shorter duration. MSP-2020 was originated by Mindset Pharma and is now under development by Otsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024. As of January 2026, MSP-2020 is in phase 1 clinical trials for major depressive disorder. MSP-2020 was patented by Mindset Pharma in 2021, though its specific chemical structure has not been disclosed and is unclear.[1–8] WP

Drug class

Serotonin receptor agonist Serotonin 5-HT2A receptor agonist Serotonergic psychedelic Hallucinogen WP

From the Wikipedia article's infobox.

Chemistry

Awaiting sourceFormula, structure and identifiers from PubChem.

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings

Awaiting sourceExperience Vault listing and report categories.

Bluelight bluelight.org

Listings

Awaiting sourceTrip report threads and this substance's discussion forum.

Reddit reddit.com

Listings

Awaiting sourceTrip report posts and the relevant subreddits.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

Journal / agency MSP 2020. 14 January 2026
Other Delving into the Latest Updates on MSP-2020 with Synapse. 12 January 2026
Other MSP-2020 Drug Profile
Other Otsuka makes psychedelics play, buying Mindset. September 2023
Journal / agency Sabnis RW. Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder. ACS Medicinal Chemistry Letters. January 2025. doi:10.1021/acsmedchemlett.4c00581 · PMID 39811142 · PMC11726355
Other 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders. 4 February 2021
Other Pharma M. Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio. 5 October 2022
Other Pharma M. Mindset Pharma Inc. Scientific Summary February 2021. February 2021

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.